Guidelines

PP2.5 Hypercoagulability in adult sickle cell patients as compared to sickle cell trait subjects and a control group

January 2016
PP3.1 Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease

January 2016
PP3.2 Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice

January 2016
PP3.3 The ‘EBMT GVHD App’ improves accuracy of graft versus host disease assessment according to NIH criteria compared to standard practice – A proof of concept

January 2016
PP3.4 Incidence of Cryptosporidium after autologous and allogeneic hematopoietic stem cell transplantation

January 2016
PP3.5 The conundrum of hematocrit measurements on hematopoietic progenitor cell apheresis products: differences between cell counters

January 2016
PP4.1 Mutation frequency of SETBP1, ASXL1 and CSF3R in myeloid malignancies: retrospective analysis of 123 patients

January 2016
PP4.2 The clinical relevance of imatinib (Im) plasma trough concentration in patients with chronic myelocytic leukemia (CML) in chronic phase. A Belgian retrospective study

January 2016
PP4.3 Detection and Monitoring of BCR-ABL1 Kinase Domain Mutations by Next Generation Sequencing

January 2016
PP4.4 A retrospective study of 109 patients with essential thrombocythemia with a focus on the delay in the diagnosis

January 2016

Top